

# **A Small Footprint and Robust Interface for Solid Phase Microextraction and Mass Spectrometry based on Vibrating Sharp-edge Spray Ionization**

*Jing Wang,<sup>[a]</sup> Chong Li,<sup>[a]</sup> Peng Li<sup>\*[a]</sup>*

[a]. C. Eugene Bennett Department of Chemistry, West Virginia University, Morgantown, WV, USA.

\* Correspondence should be addressed to P.L. (peng.li@mail.wvu.edu)

Table S1 – Low flow rates achieved by cVSSI

Table S2 – Recovery test for spiked samples

Table S3 – Data for all the calibration curves

Table S4 – Typical Therapeutic concentrations of drugs tested.

Figure S1 – Optimization of device distance to the mass spectrometer inlet

Figure S2 – Optimization of capillary angle to the mass spectrometer inlet

Figure S3 – A close up picture of the cVSSI-MS setup

Figure S4 – Comparison of mass spectra with different capillary temperature

Figure S5 – Comparison of mass spectra with different spray time

Figure S6 – Comparison of capillaries with 15  $\mu\text{m}$  and 50  $\mu\text{m}$  tip size

Figure S7 – Comparison of mass spectra obtained with glue seal and without glue

Figure S8 – Study of desorption time for 100 nM samples

Figure S9 – A full range calibration curve of SPME-cVSSI-MS for metoprolol in serum

Figure S10 – A full range calibration curve of SPME-nESI-MS for metoprolol in serum

Figure S11 – Calibration curves for 4 different drug compounds from serum samples.

<b>Frequency (kHz)</b>	<b>Amplitude (V<sub>pp</sub>)</b>	<b>Volume (μL)</b>	<b>Flow Rate (μL/min)</b>
93	7	6	0.46±0.02
93	9	6	0.58±0.03
93	11	6	0.70±0.02

Table S1 Spray flow rates of the cVSSI for a 15 μm pulled-tip capillary under different input voltage.

Analyte	Spiked Concentration (ng/mL)	Found Concentration (ng/mL)	(%) Recovery ( $\pm$ SD)
metoprolol	0.267	0.24( $\pm$ 0.01)	91( $\pm$ 4)
	6.675	5.54 ( $\pm$ 0.20)	83( $\pm$ 3)
	13.36	10.69 ( $\pm$ 0.20)	80( $\pm$ 2)
	20.25	17.62 ( $\pm$ 0.91)	87( $\pm$ 5)
	26.7	21.89 ( $\pm$ 0.99)	82( $\pm$ 4)

Table S2 Recovery test for spiked metoprolol samples at different concentrations.

Analyte	Dynamic Range (ng/mL)	Linear Curve	R <sup>2</sup>
Metoprolol	0.267-26.7	Y=0.038X-0.007	0.9968
Pindolol	0.249-24.9	Y=0.006X+0.040	0.9701
Irinotecan	0.585-58.5	Y=0.016-0.045	0.9856
Capecitabine	0.360-36.0	Y=0.010X+0.082	0.9918
Acebutolol	0.337-33.7	Y=0.010X-0.040	0.9920
Oxprenolol	0.266-26.6	Y=0.010X+0.054	0.9924

Table S3 Calibration curves for all the compounds tested.

Analyte	Therapeutic Concentration (ng/mL)	Limit of Detection of the present method (ng/mL)	Reference
Metoprolol	14 to 212	0.27	[1]
Pindolol	100	0.25	[2]
Irinotecan	1600	0.59	[3]
Capecitabine	2700 to 4000	0.36	[4]
Acebutolol	200 to 2000	0.34	[5]
Oxprenolol	680	0.27	[6]

Table S4 Typical Therapeutic concentrations of drugs tested.




Figure S1: The relationship between ion intensity and the distance to the mass spectrometer inlet. The optimal distance to the inlet was determined to be 5 mm.





Figure S2: The relationship between ion intensity and the angle to the mass spectrometer inlet. The optimal distance to the inlet was determined to be 30 degree.




Figure S3 A close up picture of the cVSSI-MS setup





Capillary Temperature: 50 °C



Capillary Temperature: 375 °C

Figure S4 Comparison of mass spectra of 10  $\mu$ M metoprolol with different capillary temperatures. Left: 50 °C; Right: 375 °C













Figure S5 Comparison of MS signals with different spray time using 10  $\mu$ M metoprolol. a) and b) ion chromatograms of a 30 s spray and a 3 s spray, respectively. c) and d) Relative intensity of each scan of a 30 s spray and a 3 s spray, respectively. e) and f) S/N of each scan of a 30 s spray and a 3 s spray, respectively. g) and h) comparison of average relative intensity and S/N of a 30 s spray and a 3 s spray, respectively.


a)




b)




c)




d)




e)



f)



g)



h)




Figure S6 Comparison of capillaries with 15  $\mu\text{m}$  and 50  $\mu\text{m}$  tip size. a) and b) microscopy images of a 15  $\mu\text{m}$  tip and a 50  $\mu\text{m}$  tip, respectively. c) and d) microscopy images of droplets generated by a 15  $\mu\text{m}$  tip and a 50  $\mu\text{m}$  tip, respectively. e) and f) size distribution of droplets generated by a 15  $\mu\text{m}$  tip and a 50  $\mu\text{m}$  tip, respectively. g) and h) comparison of mass spectra of 10  $\mu\text{M}$  metoprolol generated by a 15  $\mu\text{m}$  tip and a 50  $\mu\text{m}$  tip, respectively.




Figure S7 Comparison of mass spectra 10  $\mu$ M metoprolol obtained with glue seal (left) and without glue (right).




Figure S8 The relationship between the signal response and the desorption time with 500  $\mu\text{L}$  extraction volume, 24 min extraction time, and 6  $\mu\text{L}$  desorption volume for 100 nM and 10  $\mu\text{M}$  metoprolol samples.




Figure S9: The calibration curve for metoprolol in serum samples obtained using SPME-cVSSI-MS.






Figure S10: The calibration curve for metoprolol in serum samples obtained using SPME-nESI-MS.




Figure S11: Calibration curves for 4 different drug compounds from serum samples. (a)-(d) irinotecan, capecitabine, acebutolol, and oxprenolol, respectively.

## References:

1. Lundborg, P., Steen, B.: Plasma levels and effect on heart rate and blood pressure of metoprolol after acute oral administration in 12 geriatric patients. *Acta medica Scandinavica*. 200, 397-402 (1976)
2. Abdel-Hamid, M.E., Phillips, O.A.: LC–MS/MS Determination of Carbamazepine, Pindolol, and Theophylline in Human Serum. *Journal of Liquid Chromatography & Related Technologies*. 26, 1937-1957 (2003)
3. Satoh, T., Yasui, H., Muro, K.E.I., Komatsu, Y., Sameshima, S., Yamaguchi, K., Sugihara, K.: Pharmacokinetic Assessment of Irinotecan, SN-38, and SN-38-Glucuronide: A Substudy of the FIRIS Study. *Anticancer Research*. 33, 3845 (2013)
4. Reigner, B., Blesch, K., Weidekamm, E.: Clinical Pharmacokinetics of Capecitabine. *Clinical pharmacokinetics*. 40, 85-104 (2001)
5. Love, J.N.: Acebutolol overdose resulting in fatalities. *The Journal of emergency medicine*. 18, 341-344 (2000)
6. Bolli, P., Bühler, F.R., Raeder, E.A., Amann, F.W., Meier, M., Rogg, H., Burckhardt, D.: Lack of beta-adrenoreceptor hypersensitivity after abrupt withdrawal of long-term therapy with oxprenolol. *Circulation*. 64, 1130-1134 (1981)